Thyme

This is thyme’s best-evidenced use, and the evidence is specifically for fixed combinations. A 2015 systematic review and meta-analysis of RCTs for cough in upper-respiratory infection pooled four trials of ivy/primrose/thyme products and found a clear benefit in cough resolution (relative ratio 1.40, 95% CI 1.23–1.60), rating the evidence strong ^{1Reference 1Wagner et al. · 2015Meta-analysisHerbal Medicine for Cough: a Systematic Review and Meta-AnalysisView study →}. That signal is anchored by two large double-blind, placebo-controlled Phase IV trials in adults with acute bronchitis and productive cough: a thyme–ivy fluid extract (Bronchipret, n=361) and a thyme–primrose dry-extract tablet (n=361), both cutting bronchitis-severity scores and speeding recovery versus placebo over ~11 days ^{2,3Reference 2Kemmerich · 2007RCTEvaluation of efficacy and tolerability of a fixed combination of dry extracts of thyme herb and primrose root in adults with acute bronchitis — double-blind, placebo-controlled, randomised multicentre trialView study →Reference 3Kemmerich et al. · 2006RCTEfficacy and tolerability of a fluid extract combination of thyme herb and ivy leaves vs placebo in acute bronchitis — randomised, double-blind, placebo-controlled trialView study →}. A 2024 randomised, triple-blind trial added thyme syrup (20 mg/kg three times daily) to standard care in 60 children with asthma exacerbation and found a significant reduction in cough versus placebo ^{4Reference 4Eskandarpour et al. · 2024RCTThymus vulgaris ameliorates cough in children with asthma exacerbation — randomised, triple-blind, placebo-controlled clinical trialView study →}. Real-world observational data on a thyme/ivy extract (BNO 1200) in 305 pharmacies are consistent ^{5Reference 5Kardos et al. · 2021ObservationalEffectiveness and tolerability of the thyme/ivy herbal fluid extract BNO 1200 for acute cough — observational pharmacy-based studyView study →}, and a 2025 open-label trial compared single-ivy against two herbal combinations in acute bronchitis ^{6Reference 6Kardos et al. · 2025RCTEfficacy and Safety of a Single Ivy Extract Versus Two Herbal Extract Combinations in Acute Bronchitis — multi-center, randomised, open-label clinical trialView study →}.

Gap: the trials test thyme combined with ivy or primrose — there is no comparably powered placebo-controlled trial of a thyme monopreparation, so the herb’s solo contribution is inferred, not measured.

Thyme’s traditional reputation as an antiseptic maps onto a large and consistent in vitro literature: the phenols thymol and carvacrol disrupt bacterial membranes and show broad activity against Gram-positive and Gram-negative species, summarised across the genus in a 2015 review ^{14Reference 14Nabavi et al. · 2015ReviewPlants belonging to the genus Thymus as antibacterial agents: from farm to pharmacy — reviewView study →}. Recent work keeps extending this — carvacrol acts synergistically with quercetin against Candida-associated and bacterial biofilms in vitro ^{15Reference 15Kannan et al. · 2026In vitroQuercetin and carvacrol act synergistically to inhibit Candida albicans biofilms in vitro via membrane disruption and oxidative stressView study →}, and thyme enrichment suppressed microbial spoilage organisms in a fermented dairy matrix ^{21Reference 21Altun et al. · 2026In vitroFunctional enhancement of fermented dairy-based tarhana with Thymus vulgaris: phytochemical characterisation and in vitro antioxidant/antidiabetic potentialView study →}. The important limit is preparation and route: these are culture-dish and food-preservation results at oil-level concentrations, whereas thyme is used clinically as a tea, tincture or diluted gargle. No controlled trial shows thyme clearing a systemic bacterial infection in humans.

Gap: essentially all antibacterial data are in vitro or in food/topical models; the leap to internal clinical antimicrobial efficacy at drinkable doses is unproven.

The anti-inflammatory activity is where the respiratory use starts to look mechanistically coherent. In a rat model of LPS-induced bronchoalveolitis, a thyme–ivy syrup reduced airway leukocyte infiltration and goblet-cell hyperplasia and inhibited leukotriene production in human neutrophils ^{7Reference 7Seibel et al. · 2015AnimalBronchipret syrup containing thyme and ivy extracts suppresses bronchoalveolar inflammation and goblet-cell hyperplasia in experimental bronchoalveolitis — rat in vivo studyView study →}; a thyme–primula combination similarly showed anti-inflammatory and mucus-regulatory effects in vivo and in vitro ^{8Reference 8Seibel et al. · 2018In vitroAnti-inflammatory and mucus-regulatory activities of a fixed combination of thyme and primula extracts — in vivo and in vitroView study →}. Isolated thymol attenuated Klebsiella-induced acute lung injury in mice, dampening leukocyte infiltration and oxidative stress ^{16Reference 16Amarni et al. · 2026AnimalThymol attenuates Klebsiella pneumoniae-induced lung injury — in vivo mouse and in silico studyView study →}, and a thyme leaf extract protected against particulate-matter lung injury in mice ^{17Reference 17Lee et al. · 2025AnimalProtective effects of thyme leaf extract against particulate-matter-induced pulmonary injury in mice — animal modelView study →}. The recurring molecular theme is suppression of NF-κB signalling and downstream mediators (COX-2, leukotrienes, pro-inflammatory cytokines). One human pharmacokinetic study confirms thymol is systemically absorbed after oral dosing, which is what makes these constituent-level effects biologically relevant to swallowed preparations rather than purely theoretical ^{13Reference 13Kohlert et al. · 2002Systemic availability and pharmacokinetics of thymol in humans — clinical pharmacokinetic trialView study →}.

Gap: the in vivo data are animal models of induced injury; no human trial isolates an anti-inflammatory endpoint for thyme, so the effect is inferred from preclinical mechanism plus the combination-product cough trials.

This action is the proposed engine behind thyme’s use for spasmodic, productive cough. In isolated rat trachea, thyme extract relaxed airway smooth muscle and inhibited endothelin-induced contraction — an effect carried by the whole extract rather than thymol alone ^{11Reference 11Engelbertz et al. · 2008AnimalThyme extract, but not thymol, inhibits endothelin-induced contractions of isolated rat trachea — ex vivoView study →}. A companion study using extracts with high versus very low thymol content showed thymol modulates but does not solely account for the antispasmodic and ciliary-clearance activity, part of which is β2-receptor mediated ^{10Reference 10Begrow et al. · 2010Impact of thymol in thyme extracts on antispasmodic action and ciliary clearance — animal ex vivo studyView study →}. Essential oil of an Ethiopian Thymus species produced concentration-dependent tracheal relaxation with a defined mechanism ^{12Reference 12Rehman et al. · 2021In vitroTracheal relaxant and antimicrobial effects of the essential oil of an Ethiopian thyme species — in vitro / ex vivoView study →}. Separately, thyme extract raised mucociliary beat frequency in airway cells from COPD patients, linking the relaxant action to improved mucus clearance ^{9Reference 9Nabissi et al. · 2018In vitroThyme extract increases mucociliary-beating frequency in primary cell lines from COPD patients — in vitroView study →}.

Gap: all direct airway-relaxation evidence is ex vivo or in vitro; there is no human spirometry trial of thyme as a bronchodilator, and the effect appears to need whole-extract or standardised-phenol preparations.

Thyme extracts and their phenols are reliable radical scavengers in vitro, and the activity is reproducible across assays (DPPH, ABTS) and correlates with total phenolic content ^{21Reference 21Altun et al. · 2026In vitroFunctional enhancement of fermented dairy-based tarhana with Thymus vulgaris: phytochemical characterisation and in vitro antioxidant/antidiabetic potentialView study →}. Animal data are supportive but indirect: thyme leaf extract limited oxidative lung injury in mice ^{17Reference 17Lee et al. · 2025AnimalProtective effects of thyme leaf extract against particulate-matter-induced pulmonary injury in mice — animal modelView study →} and Thymus linearis showed cardioprotective, antioxidant effects against induced myocardial injury in rats ^{23Reference 23Arshad et al. · 2022AnimalCardioprotective potential of Thymus linearis against induced myocardial ischemia — rat in vivo studyView study →}. The mechanism is constituent-level — rosmarinic acid, thymol and the flavones apigenin and luteolin all contribute — but the endpoint is always a biomarker, not a clinical outcome.

Gap: no human study measures an antioxidant clinical endpoint for thyme; the claim is a well-replicated in vitro/animal property, not a demonstrated benefit.

Thyme oil and its phenols inhibit fungal growth in vitro, with carvacrol and thymol disrupting the fungal membrane and inducing oxidative stress. Carvacrol acted synergistically with quercetin to cut Candida albicans biofilm biomass by roughly 80% at sub-inhibitory concentrations in a 2026 study ^{15Reference 15Kannan et al. · 2026In vitroQuercetin and carvacrol act synergistically to inhibit Candida albicans biofilms in vitro via membrane disruption and oxidative stressView study →}, consistent with the herb’s traditional topical use for fungal skin conditions. As with the antibacterial data, potency is reported at essential-oil concentrations far above what a tea or tincture delivers.

Gap: activity is in vitro and formulation-dependent; there is no controlled clinical trial of thyme for a human fungal infection, and the whole-herb preparations most people use are far more dilute than the tested oils.

Thymol is a long-standing component of antiseptic mouthrinses, and a 2015 meta-analysis found an essential-oil mouthrinse significantly reduced gingivitis and plaque versus control ^{22Reference 22Araujo et al. · 2015Meta-analysisMeta-analysis of the effect of an essential-oil-containing mouthrinse on gingivitis and plaqueView study →}. The evidence is real and human — but it belongs to a fixed four-ingredient rinse (thymol with eucalyptol, menthol and methyl salicylate), so it speaks to thymol-as-antiseptic in a specific commercial product, not to Thymus vulgaris preparations. Thymol also features in chlorhexidine–thymol dental varnishes tested for caries control.

Gap: the human data are for a multi-ingredient thymol rinse, not for thyme herb; crediting thyme for the mouthrinse result overstates the preparation match.

Thyme is well tolerated at culinary and ordinary tea, tincture and syrup doses, and the fixed thyme-combination cough products used in controlled trials reported good tolerability with no serious adverse events ^{3,5Reference 3Kemmerich et al. · 2006RCTEfficacy and tolerability of a fluid extract combination of thyme herb and ivy leaves vs placebo in acute bronchitis — randomised, double-blind, placebo-controlled trialView study →Reference 5Kardos et al. · 2021ObservationalEffectiveness and tolerability of the thyme/ivy herbal fluid extract BNO 1200 for acute cough — observational pharmacy-based studyView study →}. The concentrated essential oil is a different material: taken internally undiluted or applied neat to skin it can irritate or burn mucous membranes and skin, and internal use of the neat oil should be avoided outside professional supervision. Allergic reactions are possible in people sensitised to other Lamiaceae (mint-family) plants such as oregano, sage or mint.

Scope note: no dedicated human drug-interaction study of thyme herb was identified, and no clinically significant cytochrome-P450 interaction has been established at normal doses — but this reflects absence of evidence rather than a cleared interaction profile; treat interactions as not formally assessed.